For the quarter ending 2026-03-31, RLAY had $120,571K increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Impairment of intangible asset | - | 0 | 0 | 2,300 |
| Loss on disposal of property and equipment | - | -35 | -353 | -615 |
| Net loss | -73,291 | -54,890 | -74,149 | -147,440 |
| Depreciation expense | 504 | 599 | 748 | 2,210 |
| Stock compensation expense | 10,537 | 13,067 | 15,527 | 33,825 |
| Net amortization of premiums and discounts on investments | 782 | 857 | 1,101 | 2,991 |
| Prepaid expenses and other current assets | -7,364 | -3,822 | 3,966 | -1,756 |
| Deferred revenue | - | 0 | 0 | -7,679 |
| Operating lease assets and liabilities, net | -506 | -508 | -507 | 5,287 |
| Accounts payable and accrued expenses | 3,666 | -6,534 | -507 | -4,399 |
| Change in fair value of contingent consideration liability | - | - | - | 0 |
| Other liabilities | 384 | -615 | 469 | -1,381 |
| Net cash used in operating activities | -51,112 | -44,865 | -62,119 | -128,471 |
| Purchases of property and equipment | - | 1 | -1 | 410 |
| Purchases of investments | 50,899 | 33,996 | 58,076 | 30,899 |
| Proceeds from maturities and sales of investments | 83,800 | 69,460 | 97,800 | 148,920 |
| Net cash provided by investing activities | 32,901 | 35,463 | 39,725 | 117,611 |
| Proceeds from issuance of common stock through exercise of stock options | - | 524 | - | - |
| Proceeds from issuance of common stock via employee stock purchase plan | - | 427 | 0 | 653 |
| Proceeds from issuance of common stock via at-the-market offerings, net | 137,090 | - | - | 0 |
| Proceeds from issuance of common stock through exercise of stock options | 1,675 | - | 17 | 0 |
| Proceeds from issuance of common stock through private placement, net | - | - | - | 0 |
| Net cash provided by financing activities | 138,782 | 934 | 17 | 653 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 120,571 | -8,468 | -22,377 | -10,207 |
| Cash, cash equivalents and restricted cash at beginning of period | 85,354 | 93,822 | 126,406 | - |
| Cash, cash equivalents and restricted cash at end of period | 205,925 | 85,354 | 93,822 | - |
Relay Therapeutics, Inc. (RLAY)
Relay Therapeutics, Inc. (RLAY)